-
2024-517247-31-00
5
2025-07-07
Newly Diagnosed Higher Risk Myelodysplastic Syndrome
-
2024-516615-25-00
1
2025-05-14
hepatocellular carcinoma (HCC)
-
2023-506460-14-00
5
2025-05-07
Chronic kidney disease (CKD) and hypertension.
-
2024-511495-32-00
5
2025-04-16
Chronic Phase Chronic Myeloid Leukemia
-
2024-516363-92-00
5
2025-04-08
Psychosis Associated with Alzheimer’s Disease
-
2024-514281-39-00
5
2025-02-14
Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors Express PD
-
2024-515008-38-00
5
2025-02-14
Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Expres
-
2024-513853-66-00
5
2025-02-04
KRAS/NRAS and BRAF Wildtype Recurrent, Unresectable or Metastatic Colo
-
2024-513852-13-00
5
2025-01-20
KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Col
-
2023-509637-39-00
6
2024-11-28
moderate-to-severe psoriasis
-
2024-513009-30-00
4
2024-11-21
Moderate to Severe Crohn’s Disease
-
2023-509340-10-00
5
2024-10-29
Patients with HLA-A2 positive phenotype and metastatic Non-Small Cell
-
2023-509706-30-00
5
2024-10-18
Heart failure (HF)
-
2023-507482-26-00
5
2024-10-04
Castrate-resistant prostate cancer with oligometastases on functional
-
2022-502408-57-00
5
2024-09-04
Novo metastatic hormone-sensitive prostate cancer (mHSPC) patients hav
-
2023-507486-26-00
1
2024-08-20
Advanced metastatic castration-resistant prostate cancer with prostate
-
2022-502135-19-00
4
2024-07-18
Calcific Aortic Valve Stenosis
-
2023-504151-27-00
5
2024-05-09
Psychosis associated with Alzheimer’s Disease
-
2023-503412-33-00
5
2024-03-29
Stage IIIB-IIIC or Stage IV KRAS G12C-mutant non-small cell lung cance
-
2022-502013-28-00
6
2024-03-18
Severe Community-Acquired Pneumonia
-
2022-501453-36-00
5
2024-02-23
Breast cancer
-
2022-502113-28-00
5
2024-02-01
Follicular lymphoma
-
2023-505028-74-00
5
2024-01-29
Coronary artery disease
-
2022-501515-14-00
5
2023-09-29
Newly Diagnosed Multiple Myeloma (NDMM)